Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion type Assertion NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_head.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion description "[We show that (a) APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI/AML3 in a dose-dependent manner; (b) APcK110 is a more potent inhibitor of OCI/AML3 proliferation than the clinically used Kit inhibitors imatinib and dasatinib and at least as potent as cytarabine; (c) APcK110 inhibits the phosphorylation of Kit, Stat3, Stat5, and Akt in a dose-dependent fashion, showing activity of APcK110 on Kit and its downstream signaling pathways; (d) APcK110 induces apoptosis by cleavage of caspase-3 and poly(ADP-ribose) polymerase; and (e) APcK110 inhibits proliferation of primary AML blasts in a clonogenic assay but does not affect proliferation of normal colony-forming cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_provenance.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion evidence source_evidence_literature NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_provenance.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion SIO_000772 19383925 NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_provenance.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion wasDerivedFrom befree-2016 NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_provenance.
- NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_assertion wasGeneratedBy ECO_0000203 NP733951.RAeBgyXrqZvjG8JGhdHokUC9ItFvdtPP9SBNREFKki0HE130_provenance.